Trials / Active Not Recruiting
Active Not RecruitingNCT05499013
Study to Assess SLN124 in Patients With Polycythemia Vera
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Silence Therapeutics plc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLN124 | SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA). |
| DRUG | Placebo | sodium chloride, solution for injection |
Timeline
- Start date
- 2023-01-26
- Primary completion
- 2026-09-01
- Completion
- 2030-03-01
- First posted
- 2022-08-12
- Last updated
- 2025-12-19
Locations
28 sites across 9 countries: United States, Australia, Bulgaria, Canada, Germany, Italy, Malaysia, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05499013. Inclusion in this directory is not an endorsement.